Last reviewed · How we verify
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (SUMIT-BC)
The purpose of this study is to evaluate the safety and efficacy of samuraciclib in combination with fulvestrant versus fulvestrant alone in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer.
Details
| Lead sponsor | Carrick Therapeutics Limited |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 60 |
| Start date | Thu Nov 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Aug 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Metastatic Breast Cancer
- Locally Advanced Breast Cancer
- Breast Cancer
Interventions
- Samuraciclib
- Fulvestrant
Countries
Hungary, Mexico, United States, Turkey (Türkiye), Spain